Key Points
- Director Jason Grady sold 50,000 shares at an average price of $0.65 for proceeds of $32,500 on March 23, reducing his stake by 16.66% to 250,182 shares valued at $162,618.30.
- Impact Biomedical stock opened at $0.58 and has a 12‑month trading range of $0.36 to $3.74.
- The company, through subsidiary Global BioLife, focuses on developing a universal therapeutic drug platform, a new sugar substitute, and a multi‑use fragrance.
Impact Biomedical Inc. (NYSEAMERICAN:IBO - Get Free Report) Director Jason Grady sold 50,000 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $0.65, for a total transaction of $32,500.00. Following the transaction, the director owned 250,182 shares of the company's stock, valued at $162,618.30. This trade represents a 16.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Impact Biomedical Price Performance
Impact Biomedical stock opened at $0.58 on Thursday. Impact Biomedical Inc. has a twelve month low of $0.36 and a twelve month high of $3.74.
About Impact Biomedical
(
Get Free Report)
Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
